News | October 22, 2025
RPG Life Sciences posts Q2 FY26 PAT at Rs. 36.85 Cr
RPG Life Sciences has reported total income of Rs. 186.22 crore during the period ended September 30, 2025
RPG Life Sciences has reported total income of Rs. 186.22 crore during the period ended September 30, 2025
Indegene is strengthening its Consulting Practice to help life sciences organizations address their most pressing challenges with speed, impact, and accountability
Acquisition aims to strengthen Merck's downstream process offering of advanced filtration and chromatography solutions
The collaboration combines the extensive CMC expertise of Sai Life Sciences in API development, Agility Life Sciences in formulation development, and Centrix Pharma Solutions in drug product development and clinical manufacturing
BIL also holds an option to increase its equity stake by an additional 15%
With the addition of Phase II (~91 KL) in Q1 FY26, the combined capacity of the block now stands at ~200 KL
Dr. Venkatraman brings over 25 years of experience in small molecule and Biologics drug development, manufacturing, and advancing strategic growth initiatives
Baruah will lead strategy, growth, and transformation across the HLS vertical, focusing on expanding digital health capabilities and accelerating AI adoption
Deepak has around 25 years of work experience with reputed companies viz. UPL Group, Teva Group, AkzoNobel India, Ranbaxy Laboratories, and Dr. Reddy’s Laboratories
Subscribe To Our Newsletter & Stay Updated
